EANS-Adhoc: Intercell AG / Intercell AG announces Q1 2011 results and updates on R&D progress

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

10.05.2011

Significant increase in IXIARO®/JESPECT® sales compared to Q1 2010
Cost restructuring progressing well - net loss reduced by 23.4% to EUR 11.3m

Vienna (Austria), May 10, 2011 - Today, the biotech-vaccine company Intercell AG
(VSE: ICLL) announced its financial results for Q1 and presented an update on
the Company's development programs.

Financial Results
» Year-on-year revenue growth of 19.7% driven by strong IXIARO®/JESPECT® sales
revenues
» Restructuring process progressing successfully - operating loss reduced by
33.1%
» Higher sales and reduced spending lead to reduced net loss of EUR 11.3m
» Cash position of EUR 87.7m at quarter-end
» Unchanged net loss expectation of EUR 30 - 40m for full year 2011

Key Financial Figures

TEUR                          3 months ended
                                 March 31,       Year ended
                             2011      2010      Dec 31, 2010

Revenues                     5,692     4,756        34,215
Net loss                   (11,257)  (14,702)     (255,182)
Net operating cash flow    (23,453)  (15,468)      (65,120)
Cash and available-
for-sale financial assets   87,697   158,216        86,182


IXIARO®/JESPECT®

Revenues from IXIARO®/JESPECT® product sales increased from EUR 0,4m in Q1 2010
to EUR 3.3m in Q1 2011. This excellent result in the usually weakest quarter of
the year - due to travel seasonality - reflects the positive trend of increasing
sales of IXIARO®/JESPECT® a already seen in 2010 in key travel markets and to
U.S. military.

Intercell expects a growth of sales to the U.S. military in 2011 due to higher
vaccination rates and the finally expired stock of no longer manufactured
JE-Vax®.

Intercell continues to expand the global availability of IXIARO® by increasing
the number of regulatory approvals and subsequent launches in various global
markets. Furthermore it is planning to launch the product with its partner
Novartis in additional European countries as well as Hong Kong and Singapore as
the first Asian territories during 2011.

The U.S. authorities recently confirmed to Intercell that the first
postmarketing safety evaluation of IXIARO® concluded that no new safety concerns
were identified and no labeling changes are requested at this time.

Progress in Intercell´s growing nosocomial vaccine franchise
» Next steps defined for Pseudomonas vaccine candidate: Agreement with Novartis
to advance investigational Pseudomonas vaccine into confirmatory clinical
efficacy trial in ventilated ICU patients
» Update on Staphylococcus aureus vaccine candidate: Study not futile -
pre-specified futility criteria not met in Phase II/III trial
(cardiothoracic surgery) - Independent DMC recommended suspension of
enrollment pending further analyses of the benefit/risk profile - further
update expected after completion of analyses.
» Clostridium difficile vaccine candidate - Phase I trial progressing according
to plan - First study results expected in 2011

Progress in Pandemic Influenza Vaccine Enhancement Patch (VEP) - Intercell
and GSK maintain commitment on strategic patch collaboration

IC31® adjuvant Novartis has initiated a Phase I clinical trial, combining
an undisclosed vaccine candidate with Intercell's IC31® adjuvant. Under a
Strategic Alliance Agreement signed in 2007, Novartis received a non
exclusive license for the use of IC31® in selected new vaccines.

Corporate
» Thomas Lingelbach appointed new CEO of Intercell, effective May 10, 2011;
Gerd Zettlmeissl resigns from the management board as of today

The full report can be downloaded at
http://www.intercell.com/main/forinvestors/downloads/quarterly-reports/

Further inquiry note:
Intercell AG
Nina Waibel
Corporate Communications
Tel. +43 1 20620-1222
[email protected]
end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer:      Intercell AG
             Campus Vienna Biocenter  3
             A-1030 Wien 
phone:       +43 1 20620-0
FAX:         +43 1 20620-800
mail:        [email protected] 
WWW:         www.intercell.com
sector:      Biotechnology
ISIN:        AT0000612601
indexes:     ATX Prime, ATX

stockmarkets: official market: Wien
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | OTB

print